Meetings - The ASCO Post

CHECKPOINT INHIBITORS have rapidly become the standard of care as second-line treatment, and in some patients first-line treatment, of advanced bladder cancer. However, the majority of patients do not...

Prostate Cancer

By Alice Goodman / December 10, 2018 / 2018 Annual Chemotherapy Foundation Symposium

Shedding Light on Mechanisms of Resistance to Treatment of Metastatic Castration-Resistant Prostate Cancer

ONE OF the pressing issues in metastatic castration-resistant prostate cancer is the development of resistance to therapies directed at the androgen receptor (AR), such as enzalutamide (Xtandi) and ab...

Breast Cancer

By Alice Goodman / December 10, 2018 / 2018 Annual Chemotherapy Foundation Symposium

Management of HER2-Positive Breast Cancer: Business as Usual?

MANAGEMENT OF HER2-positive breast cancer changed after the introduction of trastuzumab (Herceptin), the first anti-HER2 therapy to be approved by the U.S. Food and Drug Administration (FDA) for this ...

2018 Annual Chemotherapy Foundation Symposium

Bladder Cancer: Strategies to Address Checkpoint Inhibitor Failure

Shedding Light on Mechanisms of Resistance to Treatment of Metastatic Castration-Resistant Prostate Cancer

Management of HER2-Positive Breast Cancer: Business as Usual?

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma

Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor

Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer

Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma